NCT02785900 CASCADE (Clinical Trial/ VADASTUXIMAB TALIRINE/ SGN-CD33A/ EC-MAB)

Study Title

Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia (CASCADE) (NCT02785900)

Trial Description

The purpose of this study in AML patients is to test whether vadastuximab talirine (SGN-CD33A; 33A) combined with either azacitidine or decitabine extends overall survival longer than placebo combined with either azacitidine or decitabine.

This trial is sponsored by Seattle Genetics®.

Study Data

  • Condition: Acute Myeloid Leukemia
  • Interventions:
    • Drugs used in this trial
      • SGN-CD33A
  • Phase: I
  • Enrollment: 540
  • Start: May 2016
  • Estimated Completion: September 2021
  • Last verified: May 2017
  • Last Updated: May 2017

Study Schematic

NCT02785900

Click here to Return to Drug map

Last update: This trial is discontinued (see article June 19, 2017).


Last Editorial review: June 19, 2017
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.